Spots Global Cancer Trial Database for indolent lymphoma
Every month we try and update this database with for indolent lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma | NCT00954005 | Indolent Lympho... | Therapy with Ri... | 18 Years - | German Low Grade Lymphoma Study Group | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years | NCT03492775 | Indolent Non-ho... | Obinutuzumab Bendamustine | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | NCT04431635 | Indolent Lympho... | Copanlisib Nivolumab Rituximab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | NCT03261349 | Indolent Lympho... | Ledipasvir and ... | 20 Years - | National Taiwan University Hospital | |
| Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | NCT00493454 | Lymphoma | Zevalin Rituximab ^111 In Ibritum... | 18 Years - | M.D. Anderson Cancer Center | |
| 11C-Acetate PET/CT Non-FDG-Avid Tumors | NCT00687778 | Soft Tissue Sar... Thyroid Cancer Lung Cancer Indolent Lympho... Neuroendocrine ... GIST Uterine Maligna... Carcinoma, Hepa... Carcinoma, Lobu... Teratoma | 18 Years - 90 Years | Tel-Aviv Sourasky Medical Center | ||
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | NCT04431635 | Indolent Lympho... | Copanlisib Nivolumab Rituximab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma | NCT00086034 | Lymphoma Non-Hodgkin's L... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT01263899 | Hodgkin Lymphom... Mantle Cell Lym... Indolent Lympho... | SB1518 | 18 Years - | S*BIO | |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | NCT03424603 | B-cell Lymphoma Non Hodgkin Lym... Multiple Myelom... Follicular Lymp... Mantle Cell Lym... Diffuse Large B... Indolent Lympho... B Cells--Tumors | STRO-001 | 18 Years - | Sutro Biopharma, Inc. | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies | NCT02061761 | Hematologic Neo... | BMS-986016 BMS-936558 | 18 Years - | Bristol-Myers Squibb | |
| Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma | NCT02689869 | Indolent Non-Ho... | Ibrutinib GA 101 | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period | NCT04957693 | Indolent Lympho... | vegan diet and ... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Fludara (Oral) Phase II Study for Indolent Lymphoma | NCT00688883 | Lymphoma | Fludarabine Pho... | 20 Years - 74 Years | Sanofi | |
| Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | NCT00001512 | B Cell Lymphoma Follicular Lymp... Lymphoma | Id-KLH Vaccine GM-CSF | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma | NCT00086034 | Lymphoma Non-Hodgkin's L... | Motexafin gadol... | 18 Years - | Pharmacyclics LLC. | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies | NCT02061761 | Hematologic Neo... | BMS-986016 BMS-936558 | 18 Years - | Bristol-Myers Squibb | |
| Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | NCT00577993 | Lymphoma | Fludarabine Novantrone Decadron Rituximab Interferon Doxorubicin Vincristine Bleomycin Cyclophosphamid... Etoposide Cisplatin Ara-C Methyl-Predniso... Procarbazine Prednisone | - 76 Years | M.D. Anderson Cancer Center | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT01263899 | Hodgkin Lymphom... Mantle Cell Lym... Indolent Lympho... | SB1518 | 18 Years - | S*BIO | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | NCT03424603 | B-cell Lymphoma Non Hodgkin Lym... Multiple Myelom... Follicular Lymp... Mantle Cell Lym... Diffuse Large B... Indolent Lympho... B Cells--Tumors | STRO-001 | 18 Years - | Sutro Biopharma, Inc. | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | NCT03261349 | Indolent Lympho... | Ledipasvir and ... | 20 Years - | National Taiwan University Hospital | |
| Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | NCT00493454 | Lymphoma | Zevalin Rituximab ^111 In Ibritum... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | NCT03585725 | Follicular Lymp... Mantle Cell Lym... | Ribavirin | 18 Years - | Weill Medical College of Cornell University | |
| Low-dose Radiotherapy in iNHL | NCT05543070 | Indolent Lympho... Low-dose Radiot... | Low-dose radiot... | 18 Years - 80 Years | ChineseAMS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
